Proactive Investors - Run By Investors For Investors

ImmunoPrecise subsidiary U-Protein Express clinches license from Stanford University to manufacture protein

Wnt proteins are involved in signaling cells to divide and develop and the Wnt surrogate can be used as a growth factor in cell culture for the growing of organoids
cells
ImmunoPrecise is an antibody discovery company, which offers an array of antibody services from target analysis to pre-clinical studies

U-Protein Express, an ImmunoPrecise Antibodies Ltd subsidiary in Utrech, Netherlands, has won a victory after clinching an exclusive license from Stanford University to manufacture and sell a novel protein - Wnt surrogate Fc, a substitute for a protein known as Wnt.

Wnt proteins are involved in signaling cells to divide and develop and the Wnt surrogate can be used as a growth factor in cell culture for the growing of organoids.

READ: ImmunoPrecise Antibodies sees 56% increase in 3Q revenue as it continues to advance business

The exclusive nature of the awarded license ensures that U-Protein is the single, global manufacturer and supplier to offer the Wnt surrogate Fc to the market.

“The surrogate can be used not only as a growth factor in cell culture media for the growing of organoids but also with other cell lines,” ImmunoPrecise said in its release. “With hundreds of research groups around the world culturing organoids, the market for the Wnt surrogate Fc is strong.”

ImmunoPrecise is an antibody discovery company, which offers an array of antibody services from target analysis to pre-clinical studies.

The company operates from laboratory facilities located in Victoria, British Columbia, in collaboration with its wholly-owned subsidiaries -- U-Protein Express B.V. and ModiQuest Research, Oss, which are both in the Netherlands.

Contact Ellen Kelleher at [email protected]

 

View full IPA profile View Profile

ImmunoPrecise Antibodies Ltd Timeline

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
Scientists in a lab
January 30 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use